{'fraction_non_alphanumeric': 0.03959965187119234, 'fraction_numerical': 0.019147084421235857, 'mean_word_length': 5.368421052631579, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
P-067 Efficacy and Safety of Golimumab in Ulcerative Colitis: Experience From Two Large Boston Academic Hospitals

BACKGROUND:Golimumab is a human monoclonal antibody that binds with high affinity to both soluble and transmembrane TNF-alpha. It has recently been shown to be effective in inducing clinical response, remission, and mucosal healing in TNF-antagonist naïve patients with moderate to severe ulcerative colitis (UC). However, the efficacy of the drug in clinical practice where the majority of patients have already been treated with another TNF-antagonist is unclear. Here, we describe our experience with golimumab at 2 large tertiary referral centers, Massachusetts General Hospital (MGH) and Boston Medical Center (BMC). METHODS:We used Research Patient Data Registry (RPDR) at MGH and electronic medial records at BMC to identify patients with UC treated with golimumab. Treatment with golimumab was further confirmed by review of medical records. We also collected information on baseline characteristics, clinical symptoms, medication list, comorbid conditions, laboratory and endoscopic evaluations, previous and current treatment patterns, adverse effects, and response which was assessed by physician review of medical records. RESULTS:Through August of 2014, we identified 45 patients with UC (32 at MGH and 13 at BMC) treated with standard dosing of golimumab. The median age and duration of disease at the time of treatment initiation were 37 years (range: 23–69 years) and 8 years (range: 2–44 years), respectively. Prior treatments included mesalamine compounds (66%), thiopurines (62%), and TNF-antagonist therapy (91%), which included infliximab (N = 32), adalimumab (N = 22), or both (N = 14). Thirty-eight percent (17 of 45 patients) had partial or complete response to golimumab at 6 months. Two patients (12%) lost response after an average follow up of 8 months. There was only one reported adverse effect (arthralgia) leading to discontinuation of therapy. CONCLUSIONS:In our clinical experience, golimumab appears to be safe and effective in treatment for patients with moderate to severe UC who have previously failed infliximab and/or adalimumab. The response rate appears to be lower than the reported rate in clinical trials in TNF-antagonist naïve patients.